摘要
目的观察熊去氧胆酸纳米混悬剂治疗GGT持续升高的乙型肝炎肝硬化患者的疗效。方法 80例乙型肝炎肝硬化患者随机分为治疗组和对照组,对照组给予常规保肝治疗,治疗组在对照组的基础上加用熊去氧胆酸纳米混悬剂口服治疗,分别检测2组治疗后第2周和第4周时血清GGT水平。结果 2组不同时间点血清GGT水平差异有统计学意义,治疗组在治疗第2周和第4周时,血清GGT下降速度更快。结论熊去氧胆酸纳米混悬剂能快速、有效地降低乙型肝炎肝硬化患者持续升高的血清GGT水平。
Objective To investigate the effect of ursodeoxycholic acid nanosuspension on lowering the elevated serum GGT levels in patients with HBV-related liver cirrhosis. Methods Eighty patients with HBV-related liver cirrhosis were randomly divided into two groups, a treatment group and a control group. The patients in the control group received conventional liver-protecting therapy and those in the treatment group were given oral intake of ursodeoxycholic acid nanosuspension in addition to the conventional therapy. The serum GGT levels of the two groups were detected at week 2 and 4 of treatment. Results The differences in serum GGT levels were significant between the two groups at different time points. The serum GGT levels decreased more rapidly at week 2 and 4 of treatment in the treatment group than in the control group. Conclusion Ursodeoxycholic acid nanosuspension can lower the elevated serum GGT levels in patients with HBV-related liver cirrhosis rapidly and effectively.
出处
《传染病信息》
2012年第3期164-165,共2页
Infectious Disease Information
基金
北京市自然科学基金(7122176)
国家教育部留学人员启动基金(20100651)
关键词
乙型肝炎
肝硬化
熊脱氧胆酸
纳米混悬剂
hepatitis B
liver cirrhosis
ursodeoxycholic acid
nanosuspensions
